© 2019 Neurana Pharmaceuticals. All Rights Reserved.

Neurana Pharmaceuticals, Inc. is a privately held biotechnology pharmaceutical company focused on the treatment of neuromuscular conditions, such as acute, painful muscle spasms of the neck and back. In May 2018, Neurana completed a $60M Series A financing led by Sofinnova Ventures and icluded participation from New Leaf Venture Partners, H.I.G. BioHealth, Longitude Capital and MagnaSci Ventures.

The team at Neurana Pharmaceuticals is comprised of experienced biotech executives committed to bringing a novel therapy to patients suffering from muscle spasms

CRAIG THOMPSON
President & Chief Executive Officer
KATHY SCOTT
Chief Financial Officer
RANDALL KAYE
Chief Medical Officer

JUDY CARON – Research

TONI FOSTER – Medical Operations and Program Management

CATHERINE BRISSON – Regulatory Affairs

JIM GALLAGHER – CMC, Manufacturing

JOHNNA HANNAH – Corporate Development